Neuphoria Therapeutics Inc.
For the period ended Jun 30, 2026. Filed Sep 18, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2026 · Filed Sep 18, 2026
NEUP$2.76-0.7%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Changes in Shareholders' Equity
Consolidated Statement of Changes in Shareholders' Equity
| Stock · Additional · AccumulatedOther · Total | ||||||||
|---|---|---|---|---|---|---|---|---|
| Common Shares · Subscription · Paid-In · Comprehensive · Accumulated · Shareholders' | ||||||||
| Shares · Amount · Receivable · Capital · Loss · Deficit · Equity | ||||||||
| Balance at June 30, 2024 | 1,103,954 | $11 | $ | - | $198,481,027 | $(3,013,595) | $(177,977,071) | $17,490,372 |
| Exercise of pre-funded ADS warrant | 524,705 | 5 | - | 624 | - | - | 629 | |
| Issuance of common stock in connection with our ATM facility, net of offering costs of $0.1 million and stock subscription receivable | 349,801 | 3 | (94,685) | 1,962,485 | - | - | 1,867,803 | |
| Share issue costs | - | - | - | (339,524) | - | - | (339,524) | |
| Share-based compensation | - | - | - | 184,397 | - | - | 184,397 | |
| Other comprehensive income | - | - | - | - | 168,529 | - | 168,529 | |
| Net loss | - | - | - | - | - | (369,632) | (369,632) | |
| Balance at June 30, 2025 | 1,978,460 | $19 | $(94,685) | $200,289,009 | $(2,845,066) | $(178,346,703) | $19,002,574 | |
| Issuance of common stock in connection with our ATM facility, net of offering costs of $0.6 million | 3,398,869 | 35 | - | 17,821,163 | - | - | 17,821,198 | |
| Issuance of common stock, vested restricted stock unit awards | 34,005 | - | - | - | - | - | - | |
| Collection of subscription receivable | - | - | 94,685 | - | - | - | 94,685 | |
| Share-based compensation | - | - | - | 351,600 | - | - | 351,600 | |
| Other comprehensive income | - | - | - | - | 781,896 | - | 781,896 | |
| Net loss | - | - | - | - | - | (13,451,931) | (13,451,931) | |
| Balance at June 30, 2026 | 5,411,334 | $54 | $ | - | $218,461,772 | $(2,063,170) | $(191,798,634) | $24,600,022 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.